NIAID Funds RxBio's Development of Medical Countermeasures to Mitigate or Treat the GI-ARS after a Nuclear or Radiation Incident.
Latest News
See All News
RxBio CEO Dr. W. Shannon McCool is Featured on the "CEO Money" (Segments 2 & 3) Program Airing August 22, 2017, on World Finance News 1.
SBIR (NIH) Funds RxBio Work Assessing the Anti-Diarrheal Potential of an LPA analog Rx100
SBIR (NIH) Funds Continued Development of RxBio's Rx100 as a Novel Medical Countermeasure for Acute Radiation Syndrome.
Combined Mitigation of the Gastrointestinal and Hematopoietic Acute Radiation Syndromes by an LPA2 Receptor-Specific Nonlipid Agonist. See abstract on cell.com
Milestones
Funding Source: NIH/SBIRAmount Awarded: $222,829
Award Period: 09/17/15 - 08/31/16
Entity: RxBio
potential of a LPA
analog Rx100
Funding Source: NIH/SBIRAmount Awarded: $ 297,087
Award Period: 03/01/15 - 02/29/16
Entity: RxBio
as a Novel Medical
Countermeasure for
Acute Radiation Syndrome
Funding Source: NIH/NIAIDAmount Awarded: $6,103,776
Award Period: 09/30/13 - 04/30/17
Entity: RxBio
Countermeasures to
Mitigate or Treat
the GI-ARS after a
Nuclear or Radiation
Incident
Funding Source: NIAIDAmount Awarded: $2,392,253
Award Period: 06/15/13 - 06/14/18
Entity: UTHSC
Preclinical Development
of a New
Radiomitigator
Funding Source: BARDAAmount Awarded: $15,046,191
Award Period: 09/27/11 - 03/30/14
Entity: RxBio
Rx100 as a
Parenteral Radiomitigant
Funding Source: NCI/SBIRAmount Awarded: $194,797
Award Period: 09/23/11 - 08/22/12
Entity: RxBio
DFMO as a
radioprotector/mitigator
Funding Source: DoDAmount Awarded: $1,049,055
Award Period: 09/9/11 - 09/18/13
Entity: RxBio
Mechanism of Action
and Preclinical
Pharmacokinetic/ Pharmacodynamic
Testing in an
NHP, GI-ARS Model
Funding Source: NIAIDAmount Awarded: $2,321,862
Award Period: 10/01/09 - 09/30/11
Entity: UTHSC
of a GI Radiation
Countermeasure
Funding Source: NIH/NIAIDAmount Awarded: $231,011
Award Period: 07/22/09 - 02/28/10
Entity: RxBio
Efficacy of Rx100
in the
Gastrointestinal Tract
Funding Source: NIAIDAmount Awarded: $449,896
Award Period: 07/01/09 - 02/28/11
Entity: UTHSC
Novel GI Radiomitigator
Funding Source: CRR / UC DavAmount Awarded: $106,670
Award Period: 05/01/09 - 04/30/10
Entity: UTHSC
Novel Gastrointestinal
Radiomitigator
Funding Source: NIAIDAmount Awarded: $248,548
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing in
a radiation
combined injury
Funding Source: NIAIDAmount Awarded: $168,560
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing
in a radiation
combined injury
Funding Source: NIAIDAmount Awarded: $10,167
Award Period: 08/01/08 - 07/31/10
Entity: UTHSC
and OTP promotes
wound healing in
a radiation combined
injury
Funding Source: NIAIDAmount Awarded: $371,393
Award Period: 07/08/08 - 06/30/13
Entity: UTHSC
Radiomitigative
Cell Signaling
Funding Source: NHLBIAmount Awarded: $346,086
Award Period: 07/08/08 - 06/30/13
Entity: UTHSC
Signaling through
the GPCR-PPARgamma
Axis
Funding Source: NIH/NCIAmount Awarded: $99,999
Award Period: 06/27/08 - 11/30/08
Entity: RxBio
receptor modulator
Rx100 as a
radioprotectant
Funding Source: NIAIDAmount Awarded: $1,000,000
Award Period: 09/01/07 - 02/28/11
Entity: UTHSC
Novel GI Radiomitigator
Funding Source: NIH/NIAIDAmount Awarded: $499,999
Award Period: 09/01/07 - 03/01/09
Entity: RxBio
Efficacy of Rx100 in
the Gastrointestinal Tract
Funding Source: NIH/NDIAmount Awarded: $97,162
Award Period: 08/01/07 - 01/30/08
Entity: RxBio
Modulators as
Radioprotectants
Funding Source: NCIAmount Awarded: $285,763
Award Period: 08/01/01 - 07/31/11
Entity: UTHSC
by Phospholipid
Growth Factor
Receptors
Funding Source: NCIAmount Awarded: $285,624
Award Period: 08/01/01 - 07/31/11
Entity: UTHSC
by Phospholipid
Growth Factor
Receptors
More News
NIAID Funds Tigyi (UTHSC) Work for IND-Enabling Preclinical Development of a New RxBio Radiomitigator
McCool, RxBio Holdings team pursuing a second promising drug. Read more...
RxBio’s Shannon McCool following a non-traditional commercialization path. Read more...